Ipamorelin 3x a day: what the evidence says
No human trial has tested a three-times-daily ipamorelin protocol. Here is where the idea comes from and what is missing from the evidence.
Why we wrote this. A recurring community question about ipamorelin dosing frequency deserves a straight answer grounded in what the literature does and does not support.
In this article (5 sections)
Online forums are full of questions about pinning ipamorelin three times a day: once on waking, once before a workout, once before bed. The short answer is that no human clinical trial has tested a three-times-daily ipamorelin protocol for body composition, recovery, or any other endpoint people actually care about[1]. The idea comes from the peptide's short half-life and from animal studies that happened to use a thrice-daily schedule for unrelated reasons.
Where the three-times-a-day idea comes from
Ipamorelin is a synthetic pentapeptide that triggers a short growth-hormone pulse without meaningfully raising cortisol or prolactin, a selectivity profile that set it apart from older secretagogues like GHRP-6 when it was first characterised in 1998[2]. The GH pulse peaks around 30 to 40 minutes after a subcutaneous injection and returns to baseline within roughly two to three hours. Because each pulse is brief and discrete, people in the community reason that spacing three injections across the day would produce three separate GH elevations instead of one.
That reasoning has a basis in physiology: natural growth-hormone secretion is pulsatile, and secretagogues that preserve pulsatility are considered preferable to continuous GH infusion[3]. A 1999 rat study did administer ipamorelin subcutaneously three times daily for 15 days and observed dose-dependent increases in longitudinal bone growth, but the protocol was designed to study bone biology in rodents, not to validate a human dosing schedule[4].
What the human data actually covers
The published human evidence for ipamorelin is pharmacokinetic, not therapeutic. Early-phase studies in healthy volunteers dosed the peptide at single or repeated subcutaneous injections in the 0.5 to 10 mcg/kg range to characterise the GH and IGF-1 response[2]. Those studies confirmed a modest, short-lived GH pulse with the expected selectivity (low cortisol and prolactin disturbance), but they were not designed to measure outcomes like lean mass, fat loss, recovery speed, or sleep quality. There is no published phase-2 or phase-3 trial of ipamorelin for any indication.
A phase-2 trial for postoperative ileus (bowel recovery after surgery) was completed by Helsinn Therapeutics in 2009, but its results were never published in a peer-reviewed journal, and the compound was not advanced further. That trial used intravenous dosing in a hospital setting, which tells us little about subcutaneous self-administration for body composition.
The gaps that matter for anyone considering this
There is no human data establishing a therapeutic dose-response curve for ipamorelin at any frequency. The community numbers (typically cited as 100 to 300 mcg per injection, one to three times daily) are extrapolated from preclinical work and anecdotal reports, not from controlled trials[1]. Long-term safety data in humans does not exist. The metabolic, endocrine, and oncologic consequences of repeated daily dosing for months or years are uncharacterised.
Eric Topol, writing in Ground Truths in July 2025, placed ipamorelin among growth-hormone-related peptides that "carry the potential risk of cancer" because they induce broad cell growth, and noted that "there is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated"[5]. That framing applies whether you inject once or three times a day.
Practical reality of a three-dose schedule
Even setting the evidence question aside, a three-times-daily subcutaneous injection schedule creates practical friction. Each dose ideally falls in a fasted window (food, especially carbohydrates and fats, can blunt the GH response to secretagogues). Fitting three fasted windows around meals, sleep, and training is logistically demanding. This is one reason the community's most common protocol settles on once or twice daily (before bed and/or on waking), not three times.
Ipamorelin is not approved by any regulator in our coverage area. It is not authorised by the FDA, the EMA, the MHRA, or any national agency in the EU or EEA. It sits on the WADA Prohibited List under section S2 (growth-hormone secretagogues) and circulates as a grey-market research chemical with no regulated supply chain[2].
Where this leaves the question
Can you inject ipamorelin three times a day? People do. Should you? That is a question for a clinician who knows your history, not for a Reddit thread or this article. What we can say is that the evidence base for ipamorelin at any dosing frequency is thin, the long-term safety profile is unknown, and the supply chain is unregulated. More injections per day does not fix any of those problems. For the full regulatory and evidence picture, see the ipamorelin page and the ipamorelin regulation section.
Frequently asked
Is there a clinical trial supporting ipamorelin three times a day?
No. A 1999 rat study used a three-times-daily schedule to study bone growth, and a phase-2 human trial tested intravenous ipamorelin for postoperative ileus, but no published human trial has tested subcutaneous ipamorelin at any frequency for body composition, recovery, or sleep.
Why do people inject ipamorelin multiple times a day?
Because ipamorelin produces a short growth-hormone pulse (roughly two to three hours) and natural GH secretion is pulsatile. The reasoning is that multiple injections produce multiple discrete GH pulses across the day. This is physiologically plausible but clinically unvalidated in humans.
Does ipamorelin raise cortisol or prolactin?
In the original 1998 characterisation study, ipamorelin did not raise ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold above the effective dose for GH release. Prolactin, FSH, LH, and TSH were similarly unaffected.
Is ipamorelin approved anywhere as a medicine?
No. It is not approved by the FDA, the EMA, the MHRA, or any national agency in our coverage area. It circulates as a grey-market research chemical. The FDA Pharmacy Compounding Advisory Committee reviewed its eligibility for compounding under section 503A in October 2024, but compounding eligibility is not the same as drug approval.
Sources
- [1]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53Tier 1 · primary↩
- [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61Tier 1 · primary↩
- [3]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues (pulsatile GH release discussion). Sex Med Rev. 2018;6(1):45-53Tier 1 · primary↩
- [4]Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13Tier 1 · primary↩
- [5]Topol E. The Peptide Craze. Ground Truths (Substack). July 20, 2025Tier 2 · expert↩
No revisions yet. First published .